• Roivant Sciences Ltd ROIV.OQ reported a quarterly adjusted loss of 33 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 12 cents. The mean expectation of eight analysts for the quarter was for a loss of 31 cents per share. Wall Street expected results to range from -40 cents to -24 cents per share.

• Revenue fell 96.1% to $2.17 million from a year ago; analysts expected $7.23 million.

• Roivant Sciences Ltd's reported EPS for the quarter was a loss of 33 cents​.

• The company reported a quarterly loss of $223.36 million.

• Roivant Sciences Ltd shares had risen by 2.0% this quarter and lost 2.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 34.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Roivant Sciences Ltd is $17.50, about 34.3% above its last closing price of $11.49

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)